Cognito Therapeutics, which is in late-stage development of its device to treat neurodegenerative diseases like Alzheimer’s, hauled in ...
Medical Device Network on MSN
Cognito Therapeutics raises $105M for Alzheimer’s therapeutic advancement
With a pivotal trial readout for Cognito’s Spectris due later this year, the company anticipates launching the Alzheimer’s ...
Spectris AD™ meaningfully reduced functional and cognitive decline in Alzheimer’s Disease over 6 months compared to sham treatment and was associated with 60-84% time savings. OVERTURE I Phase 2 MRI ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the publication of a study in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results